Funding Opportunities
The Dystonia Medical Research Foundation (DMRF) encourages and supports research related to the causes, mechanisms, prevention, and treatment of all forms of dystonia, the third most common movement disorder. Through a peer-review process, all applications are reviewed and ranked by the DMRF’s Medical and Scientific Advisory Council, who then make recommendations to the Board of the Directors for funding. Types of Awards Fellowships A two-year Fellowship is designed to assist post-doctoral fellows establish careers in research relevant to dystonia. The DMRF supports hypothesis-driven research at the genetic, molecular, cellular, systems, or behavioral levels that may lead to a better understanding of the pathophysiology of dystonia or to new therapies for dystonia. Funding for fellowships is $50,000 per year for two years. Research Grants Research grants are available in support of hypothesis-driven research at the genetic, molecular, cellular, systems, or behavioral levels that may directly or indirectly lead to a better understanding of the pathophysiology and to new therapies for any or all forms of dystonia. Although early-onset primary generalized dystonia is of special interest, we also support studies on the focal dystonias, including laryngeal dystonia/spasmodic dysphonia, as well as secondary dystonias. Funding for grants is available up to $65,000 per year for 1 or 2 years. The deadline for grant and fellowship applications is December 15, 2008. Applications and guidelines will be available September 15.
Dystonia Medical Research FoundationNational Headquarters One East Wacker Drive, Suite 2810 Chicago, Illinois 60601-1905 Phone: 312-755-0198 Toll free: 800-377-DYST (3978) In Canada: 800-361-8061 Fax: 312-803-0138 Email: dystonia@dystonia-foundation.org
Therapeutics Development Initiative 2009 Pre-Proposal Receipt Date: January 20, 2009 – 6:00pm US ETThe Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the launch of its Therapeutics Development Initiative (TDI) for Spring 2009, a funding mechanism to support and stimulate preclinical Parkinson’s disease research at for-profit institutions. This funding program seeks to support preclinical development of Parkinson’s disease therapies which have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the principal investigator who must be an employee of a for-profit entity. Academic investigators may have an advisory role in the project, but the operational and strategic ownership of the project must reside within the company. Investigators may seek up to two years of funding for preclinical development and testing of novel therapeutic approaches for the treatment or prevention of Parkinson’s disease. Please note that pre-proposals are mandatory and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFP. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application. MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly. Conference Call MJFF will hold a 45 minute long conference call on December 16, 2008 at 12:00 PM U.S. Eastern Time to clarify and explain the Therapeutics Development Initiative 2009 program and to answer applicants' questions. To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details.
While there are no restrictions as to the specific approaches to be studied under this RFP, successful applications are most likely to focus on at least one of the following categories: o Neuroprotective strategies focused on slowing or preventing the process of neuronal death. o Neuroregenerative strategies to restore or replace neuronal function. o Novel drug delivery mechanisms and/or surgical procedures. o Innovative therapeutic approaches to treat the motor and non-motor symptoms of PD, including cognitive dysfunction, autonomic dysfunction, sleep disorders, or depression among others. o Therapeutic approaches to alleviate complications of PD treatment including dyskinesias, etc.
If you would like to contact the Foundation, please call toll-free at 1-800-708-7644, or contact us by regular mail at the following address: The Michael J. Fox Foundation for Parkinson's Research Church Street Station P.O. Box 780 New York, NY 10008-0780
The FSH Society, Inc. (the “Society”) sponsors research programs to meet needs of critical importance in the research of facioscapulohumeral muscular dystrophy ("FSHD"). Each year, the Society will accept requests for research funding. All proposals are subject to peer review to identify the most meritorious and innovative to be funded. The following programs are available to support research efforts: A. Research Fellowships -- provide support for graduate student researchers at any stage of their research career. B. Targeted Project Research Grants -- provide one-time support for research projects proposed by investigators at any stage of their independent research career. C. Research Opportunity Grants -- provide rapid, one-time funding of novel ideas for finding a solution to urgent problems with immediate human benefit.
APPLICATION DEADLINE There are no deadlines for the filing of fellowship and grant applications. Meritorious proposals are funded as resources and time permit at the sole and absolute discretion of the Society. An applicant whose fellowship or grant application was rejected is encouraged to discuss with the Society the feasibility of a revised application. Revised applications will be reviewed in the same detail and compete on an equal basis with new applications.
Mailing Address FSH Society, Inc. BBRI R353 64 Grove Street Watertown, MA 02472 USA Telephone (617) 658-7878 or (781) 275-7781 Office hours are Monday through Friday, 9 AM to 5 PM EST. Voicemail messages may be left after hours. Fax (617) 658-7879 or (781) 275-7789 e-mail info@fshsociety.org
Grant requests For all grant requests other than the Brighter Tomorrow grant
The initial contact should be made by letter of inquiry stating the amount sought, purpose of the grant, and nature of the organization requesting the grant. Please include an e-mail address if available. The letter should be sent to: The Grant Committee c/o Managing Director Multiple Sclerosis Foundation 6350 North Andrews Avenue Ft. Lauderdale, Fl. 33309 If you are awarded a grant we do ask as a minimum that you provide us with semi-annual progress reports however additional criteria may apply depending on the amount and type of grant. FUNDING CYCLE All grant requests excluding the Brighter Tomorrow grant, must be received prior to November 1 of each year. If your request is funded, funding will occur prior to January 15 of the following year. LIMITATIONS AND EXCLUSIONS The Multiple Sclerosis Foundation, at its sole discretion, has the right to limit, refuse or cancel any grants made. The awarding of grants is at the determination of the Multiple Sclerosis Foundation.
12next
